biostudies-literatureBanaszewska BNICHD NIH HHS4938-45https://www.ebi.ac.uk/biostudies/studies/S-EPMC2795658biostudies-literatureUnknown94(12)<h4>Context</h4>Polycystic ovary syndrome (PCOS) is characterized by ovarian dysfunction and hyperandrogenism; it is also associated with increased cardiovascular risks such as adverse lipid profile and endothelial dysfunction. Metformin and, more recently, statins have been shown to improve endocrine and metabolic aspects of PCOS.<h4>Objective</h4>The aim of the study was to compare effects of simvastatin and metformin on PCOS.<h4>Design</h4>In a prospective trial, women with PCOS (n = 136) were randomized to simvastatin (S), metformin (M), or simvastatin plus metformin (SM) groups. Evaluations were performed at baseline and after 3 months.<h4>Setting</h4>The study was conducted at an academic medical center.<h4>Primary outcome</h4>The change of serum total testosterone was measured.<h4>Results</h4>The study was completed by 113 subjects. Total testosterone decreased significantly and comparably in all groups: by 17.1, 13.6, and 15.1%, respectively, in the S, M, and SM groups. Significant decreases were also observed in all groups with respect to body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1. DHEAS declined significantly only in the S group. None of the treatments were associated with significant changes in LH or FSH. Total cholesterol and low-density lipoprotein cholesterol significantly declined only in S and SM groups.<h4>Conclusions</h4>Simvastatin treatment was superior to metformin alone, whereas a combination of simvastatin and metformin was not significantly superior to simvastatin alone.The Journal of clinical endocrinology and metabolismComparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial.PMC2795658R01 HD050656Pawelczyk LDuleba AJBanaszewska BSpaczynski RZfalseComparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial.<h4>Context</h4>Polycystic ovary syndrome (PCOS) is characterized by ovarian dysfunction and hyperandrogenism; it is also associated with increased cardiovascular risks such as adverse lipid profile and endothelial dysfunction. Metformin and, more recently, statins have been shown to improve endocrine and metabolic aspects of PCOS.<h4>Objective</h4>The aim of the study was to compare effects of simvastatin and metformin on PCOS.<h4>Design</h4>In a prospective trial, women with PCOS (n = 136) were randomized to simvastatin (S), metformin (M), or simvastatin plus metformin (SM) groups. Evaluations were performed at baseline and after 3 months.<h4>Setting</h4>The study was conducted at an academic medical center.<h4>Primary outcome</h4>The change of serum total testosterone was measured.<h4>Results</h4>The study was completed by 113 subjects. Total testosterone decreased significantly and comparably in all groups: by 17.1, 13.6, and 15.1%, respectively, in the S, M, and SM groups. Significant decreases were also observed in all groups with respect to body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1. DHEAS declined significantly only in the S group. None of the treatments were associated with significant changes in LH or FSH. Total cholesterol and low-density lipoprotein cholesterol significantly declined only in S and SM groups.<h4>Conclusions</h4>Simvastatin treatment was superior to metformin alone, whereas a combination of simvastatin and metformin was not significantly superior to simvastatin alone.2009-01-01T00:00:00Z2009 Dec2024-12-03T19:00:41.97Z2019-03-27T00:27:28ZS-EPMC27956581989002210.1210/jc.2009-1674